http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Vikash Kumar Shah,Sam-Shik Na,Myong-Soo Chong,Jae-Hoon Woo,Yeong-Ok Kwon,Mi Kyeong Lee,Ki-Wan Oh 충북대학교 동물의학연구소 2015 Journal of Biomedical and Translational Research Vol.16 No.3
Poria cocos is a well-known traditional Chinese traditional medicine (TCM) that grows around roots of pine trees in China, Korea, Japan, and North America. Poria cocos has been used in Asian countries to treat insomnia as either a single herb or part of an herbal formula. In a previous experiment, pachymic acid (PA), an active constituent of Poria cocos ethanol extract (PCE), increased pentobarbital-induced sleeping behaviors. The aim of this experiment was to evaluate whether or not PCE and PA modulate sleep architectures in rats as well as whether or not their effects are mediated through GABAA-ergic transmission. PCE and PA were orally administered to individual rats 7 days after surgical implantation of a transmitter, and sleep architectures were recorded by Telemetric Cortical encephalogram (EEG) upon oral administration of test drugs. PCE and PA increased total sleep time and non-rapid eye movement (NREM) sleep as well as reduced numbers of sleep/wake cycles recorded by EEG. Furthermore, PCE increased intracellular chloride levels, GAD65/67 protein levels, and α-, β-, and γ-subunits of GABAA receptors in primary cultured hypothalamic neuronal cells. These data suggest that PCE modulates sleep architectures via activation of GABAA-ergic systems. Further, as PA is an active component of PCE, they may have the same pharmacological effects.
CASE REPORT : A Case of Ulcerative Colitis Patient with Colonic Stenosis and Enterocutaneous Fistula
( Seong Yeon Jeong ),( You Sun Kim ),( Kyeong Sam Ok ),( Sun Ok Kwon ),( Jin Nam Kim ),( Jeong Seop Moon ),( Yun Kyung Kang ),( Seong Woo Hong ) 대한장연구학회 2012 Intestinal Research Vol.10 No.4
Ulcerative colitis (UC) is one of the chronic inflammatory bowel diseases (IBD), characterized by a diffuse mucosal inflammation limited to the colon. Complications of UC include stricture, colorectal cancer, and toxic colitis. UC patients rarely present with a stenosis or fistula, and strictures develop in less than 5% of patients with UC. We present a patient with UC, accompanied by unusual complications that involved not only a stricture but also a fistula and abscess. A 49-year-old female was presented with a left flank pain and fever that had begun two weeks before admission. She had received a diagnosis of UC 20 years ago and had it treated for 2 years in a local hospital. However, she arbitrarily stopped visiting the hospital and relied on home remedies. An abdominopelvic CT scan revealed luminal narrowing and extra-peritoneal fistula formation in the descending colon. Fistula was connected with a subcutaneous abscess in the left flank. She had undergone total colectomy and ileo-anal anastomosis. On the pathologic exam, the long standing UC with severe stenosis was observed without malignant change. It cannot be emphasized enough that a correct therapeutic approach and an appropriate follow-up schedule are very important for patients with UC. (Intest Res 2012;10:388-391)
( Jung Wha Chung ),( Gi Hyun Kim ),( Jong Ho Lee ),( Kyeong Sam Ok ),( Eun Sun Jang ),( Sook Hyang Jeong ),( Jin Wook Kim ) 대한간학회 2014 Clinical and Molecular Hepatology(대한간학회지) Vol.20 No.4
Background/Aims: Portal-vein thrombosis (PVT) develops in 10-25% of cirrhotic patients and may aggravate portal hypertension. There are few data regarding the effects of anticoagulation on nonmalignant PVT in liver cirrhosis. The aim of this study was to elucidate the safety, efficacy, and predictors of response to anticoagulation therapy in cirrhotic patients. Methods: Patients with liver cirrhosis and nonmalignant PVT were identified by a hospital electronic medical record system (called BESTCARE). Patients with malignant PVT, Budd-Chiari syndrome, underlying primary hematologic disorders, or preexisting extrahepatic thrombosis were excluded from the analysis. Patients were divided into two groups (treatment and nontreatment), and propensity score matching analysis was performed to identify control patients. The sizes of the thrombus and spleen were evaluated using multidetector computed tomography . Results: Twenty-eight patients were enrolled in this study between 2003 and 2014: 14 patients who received warfarin for nonmalignant PVT and 14 patients who received no anticoagulation. After 112 days of treatment, 11 patients exhibited significantly higher response rates (complete in 6 and partial in 5) compared to the control patients, with decreases in thrombus size of >30%. Compared to nonresponders, the 11 responders were older, and had a thinner spleen and fewer episodes of previous endoscopic variceal ligations, whereas pretreatment liver function and changes in prothrombin time after anticoagulation did not differ significantly between the two groups. Two patients died after warfarin therapy, but the causes of death were not related to anticoagulation. Conclusions: Warfarin can be safely administered to cirrhotic patients with nonmalignant PVT. The presence of preexisting portal hypertension is a predictor of nonresponse to anticoagulation. (Clin Mol Hepatol 2014;20:384-391)
( Gi Hyun Kim ),( Jung Wha Chung ),( Jong Ho Lee ),( Kyeong Sam Ok ),( Eun Sun Jang ),( Jaihwan Kim ),( Cheol Min Shin ),( Young Soo Park ),( Jin Hyeok Hwang ),( Sook Hyang Jeong ),( Nayoung Kim ),( D 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.4
Background/Aims: Vitamin E improves the biochemical profiles and liver histology in nonalcoholic steatohepatitis, but the role of vitamin E is not clearly defined in the management of nonalcoholic fatty liver disease (NAFLD) which includes both simple steatosis and steatohepatitis. Co-morbid metabolic syndrome increases the probability of steatohepatitis in NAFLD. In this study, we aimed to determine the short-term effects of vitamin E and off-treatment durability of response in a propensity-score matched cohort of NAFLD patients with metabolic syndrome. Methods: A retrospective cohort was constructed by retrieving 526 consecutive NAFLD patients from the electronic medical record data warehouse of a tertiary referral hospital in South Korea. Among them, 335 patients (63.7%) had metabolic syndrome and were eligible for vitamin E therapy. In order to assess the effect of vitamin E, propensity score matching was used by matching covariates between control patients (n=250) and patients who received vitamin E (n=85). Results: The PS-matched vitamin E group (n=58) and control group (n=58) exhibited similar baseline metabolic profiles. After 6 months of vitamin E therapy, the mean ALT levels decreased significantly compared to PS-matched control (P<0.01). The changes in metabolic profiles (body weight, lipid and glucose levels) did not differ between control and vitamin E groups during the study period. Conclusions: Short-term vitamin E treatment significantly reduces ALT levels in NAFLD patients with metabolic syndrome, but metabolic profiles are not affected by vitamin E. (Clin Mol Hepatol 2015;21:379-386)
( Dong Won Park ),( Soo Hyung Ryu ),( Myung Ki Oh ),( Seong Yeon Jeong ),( Kyeong Sam Ok ),( Jae Chan Shim ),( Jin Nam Kim ),( You Sun Kim ),( Jeong Seop Moon ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Hemangioma is the most common benign hepatic tumor. Many hepatic hemangiomas tend to be found incidentally, but should be differentiated from malignant tumors. We report an interesting case of hepatic hemangioma in patient who has high risks of hepatocellular carcinoma. Case: A 52-year-old woman, who was a chronic alcoholic abuser and hepatitis C virus carrier with no treatment experience, was admitted due to diarrhea. The patient had suffered from intermittent abdominal pain in the right subcostal area for recent 3 months. Also the patient had easy bruising and frequent epistaxis. She had used oral contraceptives for almost 20 years. Systolic blood pressure was 160 mmHg and diastolic blood pressure was 80 mmHg. Body temperature was normal. Physical examination revealed icteric sclerae and tenderness in right upper quadrant of the abdomen. Laboratory study showed platelet count of 31,000/ul, AST/ALT of 302/127 IU/L, and total bilirubin of 2.7 mg/dl. 3-phased contrast-enhanced abdominal computed tomography (CT) revealed a 4 cm × 4 cm sized hepatic mass involving both segment 5 and 6. Abdominal CT finding suggested hepatic hemangioma, however, typical finding of hemagioma was unclear, therefore, could not rule out the malignancy. Since she had risk factors for hepatocellular carcinoma, abdominal ultrasonography was performed for further evaluation. But abdominal ultrasonography also showed atypical finding. The confirmative diagnosis could be done by dynamic magnetic resonance imaging (MRI) using primovist®, which is an innovative liver cell-specific contrast medium. Dynamic MRI presented peripheral globular enhancement and a centripetal fill-in pattern, confirmatory findings of hepatic hemangioma, on the delayed image. The patient got relief from abdominal pain and diarrhea during admission, now is being followed-up at a general out-patient clinics. Conclusions: Hemangiomas with atypical abdominal CT and ultrasonographic findings in patients with high risks of hepatocellular carcinoma can be easily characterized with primovist-enhanced dynamic MRI.